Casdatifan - Arcus Biosciences
Alternative Names: AB-521; HIF-2a inhibitor - Arcus BiosciencesLatest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator Arcus Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Endothelial PAS domain-containing protein 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Renal cell carcinoma; Solid tumours
- Phase I Cancer
- Preclinical Liver cancer
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for phase-I development in Cancer(In volunteers) in Netherlands (PO, Capsule)
- 06 Nov 2024 Arcus Biosciences completes a successful Type B meeting with the US FDA to discuss its first Phase III PEAK-1 trial
- 25 Oct 2024 Updated adverse events and efficacy data from a phase I/Ib trial in Renal cell carcinoma released by Arcus Biosciences